



Corp. Off. 'Orchid Towers' 313, ValluvarKottam High Road, Nungambakkam, Chennai - 600 034, India. Tel : (91) - 44- 2821 1000 Fax : (91) - 44 - 2821 1002

November 09, 2012

The Manager
Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, 5th Floor, Plot No: C/1
G - Block, Bandra - Kurla Complex
Bandra (East), Mumbai - 400 051

Dear Sirs,

Sub: Unaudited Financial Results for the Quarter/Half year ended 30th September, 2012

In accordance with the Clause 41 of the listing agreement, we are enclosing the following

- ❖ Copy of the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2012 along with the press release in this respect.
- ❖ Copy of the limited review report on the aforesaid Unaudited Financial Results as issued by the Statutory Auditors of the Company.

The above Unaudited Financial Results and the limited review report have been taken on record by the Board of Directors at their meeting held on November 09, 2012.

This is for your information and records.

Thanking you,

Yours faithfully,

A handwritten signature in black ink, appearing to read 'Bhoomijha Murali'.

Bhoomijha Murali
Sr. GM – Legal & Company Secretary

Encl.: a/a



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR / QUARTER ENDED SEPTEMBER 30, 2012

Orchid Chemicals
& Pharmaceuticals Limited

Rs. lakhs

S. No.	Particulars	Standalone					
		Unaudited					Audited
		Three months ended 30-Sep-12	Three months ended 30-Jun-12	Three months ended 30-Sep-11	Six months ended 30-Sep-12	Six months ended 30-Sep-11	Year ended 31-Mar-12
1	Income from Operations						
	a) Net Sales / Income from Operations (Net of Excise Duty)	33054.81	31563.15	41222.25	64617.96	78598.27	170170.80
	b) Other Operating Income	-	4159.90	726.97	4159.90	1709.84	6293.47
	c) Total Income from operations (Net) (a+b)	33054.81	35723.05	41949.22	68777.86	80308.11	176464.27
2	Expenses						
	a) Cost of materials consumed	15202.02	10193.28	18363.10	25395.30	40341.92	80241.50
	b) Purchases of stock-in-trade	1420.27	1538.32	1129.29	2958.59	2564.83	4546.38
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(914.03)	7204.14	(641.03)	6290.11	(5487.43)	(6201.86)
	d) Employee benefit expense	4130.37	3761.80	3568.60	7892.17	7435.39	15464.59
	e) Depreciation / Amortisation	3955.09	3991.26	3597.59	7946.35	7128.06	14905.56
	f) Other Expenses	9272.27	7444.46	8938.37	16716.73	16097.67	41242.32
	g) Total Expenses	33065.99	34133.26	34955.92	67199.25	68080.44	150198.49
3	Profit/(Loss) from operations before other income, finance costs, exceptional items (1-2)	(11.18)	1589.79	6993.30	1578.61	12227.67	26265.78
4	Other Income	1.31	-	1.30	1.31	1.30	1.59
5	Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)	(9.87)	1589.79	6994.60	1579.92	12228.97	26267.37
6	Finance costs	7647.05	7132.59	4006.69	14779.64	7081.43	17905.29
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	(7656.92)	(5542.80)	2987.91	(13199.72)	5147.54	8362.08
8	Exceptional Items - Gain / (Loss)	4621.98	(808.04)	(8644.71)	3813.94	(8819.27)	(8388.14)
9	Profit/(Loss) from ordinary activities before Tax (7+8)	(3034.94)	(6350.84)	(5656.80)	(9385.78)	(3671.73)	(26.06)
10	Tax expenses						
	- Current Tax & Deferred Tax	(1040.33)	(1270.66)	-	(2310.99)	430.82	(2337.22)
11	Net Profit/(Loss) from ordinary activities after Tax (9-10)	(1994.61)	(5080.18)	(5656.80)	(7074.79)	(4102.55)	2311.16
12	Extraordinary item (net of tax expenses Rs.nil)	-	-	8000.00	-	8000.00	8000.00
13	Net Profit/(Loss) for the period (11+12)	(1994.61)	(5080.18)	2343.20	(7074.79)	3897.45	10311.16
14	Paid-up Equity Share Capital (Face value of Rs.10/- each)	7045.21	7045.21	7044.21	7045.21	7044.21	7044.21
15	Reserves excluding Revaluation Reserves	-	-	-	-	-	112410.89
16	Earnings per share (EPS) before extra-ordinary items of Rs.10/- each						
	- Basic Rs.	(2.83)*	(7.21)*	(8.03)*	(10.04)*	(5.82)*	3.28
	- Diluted Rs.	(2.83)*	(7.21)*	(8.03)*	(10.04)*	(5.82)*	3.24
17	Earnings per share (EPS) after extra-ordinary items of Rs.10/- each						
	- Basic Rs.	(2.83)*	(7.21)*	3.33*	(10.04)*	5.53*	14.64
	- Diluted Rs.	(2.83)*	(7.21)*	2.75*	(10.04)*	4.57*	14.46
A	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding						
	- Number of equity shares	47611295	47611295	49427854	47611295	49427854	47601295
	- Percentage of Shareholding	67.58	67.58	70.17	67.58	70.17	67.57
2	Promoters and Promoter group shareholding						
a.	Pledged / Encumbered						
	- Number of shares	17676037	17110383	16210383	17676037	16210383	17060383
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	77.39	74.91	77.14	77.39	77.14	74.69
	- Percentage of shares (as a % of the total share capital of the company)	25.09	24.29	23.01	25.09	23.01	24.22
b.	Non - Encumbered						
	- Number of shares	5164744	5730398	4803839	5164744	4803839	5780398
	- Percentage of shares (as a % of the total shareholding of the promoter and promoter group)	22.61	25.09	22.86	22.61	22.86	25.31
	- Percentage of shares (as a % of the total share capital of the company)	7.33	8.13	6.82	7.33	6.82	8.21
B	INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter						
	Received during the quarter						
	Disposed off during the quarter						
	Remaining unresolved at the end of the quarter						

3 Months ended 30-Sep-2012


- NIL -


32

32

- NIL -



* EPS for the period (not annualised)						
The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 09, 2012 and have been subjected to limited review by the Statutory Auditors in terms of Clause 41 of the Listing Agreement.						
The Company is operating in single segment (i.e) "Pharmaceuticals".						
Consolidated Results of the company						
	Three months ended	Three months ended	Three months ended	Six months ended	Six months ended	Year ended
	30-Sep-12	30-Jun-12	30-Sep-11	30-Sep-12	30-Sep-11	31-Mar-12
Total Operating Income	37837.16	40670.74	46571.68	78507.90	91494.89	190199.09
EBIDTA	8365.54	4602.86	9797.09	12968.40	18691.32	40892.58
Profit After Tax	(2400.25)	(5402.51)	2072.81	(7802.77)	3765.06	8747.84
The Company has entered into a Business Transfer Agreement (BTA) dated August 29, 2012 with Hospira Healthcare India Private Limited for the sale and transfer of Orchid's Penicillin and Penem API business and the API facility located in Aurangabad (Maharashtra) together with an associated Process R&D infrastructure located in Chennai.						
The Board has approved the transfer of Orchid's 50% equity holding of its Joint venture NCPC, Orchid Pharmaceuticals Co.Ltd, China to Joint Venture partner in China.						
Exceptional items for the quarter ended September 30, 2012 represents profit on sale of Investments in the Joint Venture in China of Rs. 5126.48 lakhs (Previous period - Rs. NIL), exchange loss on FCCBs / FCTLs of Rs.504.5 lakhs (Corresponding quarter - Loss of Rs. 7582.30 lakhs) and one time closure cost of Alathur Plant for the quarter ended September 2012 is Rs. NIL (Previous period - Rs.1129.71 lakhs). The Company had exercised the option provided under the Amendment to the Companies (Accounting Standards) Amendments Rules, 2006 dated March 31, 2009. The Ministry of Corporate Affairs vide notification dated 29th December 2011 has extended the amortisation of gains or losses arising on reporting of Foreign Currency Monetary items over the balance period of such long term asset / liability. Accordingly Exchange Loss on long term foreign currency loans have been amortised over the balance period of such loans. The amount remaining to be amortized in the financial statements as at September 30, 2012 on account of exercising the above option is Rs.7883.02 lakhs (Corresponding period ended - Rs.NIL).						
Previous period figures have been regrouped wherever necessary.						
For and on behalf of the Board						
 S Krishnan Executive Director - Finance						
Place : Chennai						
Date : November 09, 2012						

STATEMENT OF ASSETS AND LIABILITIES			
Rs. lakhs			
Particulars	Standalone		
	Audited		
	As at 30-Sep-12	As at 31-Mar-12	
A EQUITY AND LIABILITIES			
1 Shareholders' funds			
(a) Share Capital	7045.21	7044.21	
(b) Reserves and Surplus	105351.70	112410.88	
Sub-total- Shareholders' funds	112396.91	119455.09	
2 Non-current liabilities			
(a) Long-term borrowings	83529.76	107414.70	
(b) Deferred tax liabilities (net)	14807.35	17118.34	
(c) Other long-term liabilities	5447.61	4634.08	
(d) Long-term provisions	771.97	771.97	
Sub-total- Non-current liabilities	104556.69	129939.09	
3 Current liabilities			
(a) Short-term borrowings	78578.07	63788.32	
(b) Trade payables	27178.81	35763.29	
(c) Other current liabilities	66340.78	40654.62	
(d) Short-term provisions	3998.92	5089.10	
Sub-total-Current liabilities	176096.58	145295.33	
TOTAL-EQUITY AND LIABILITIES	393050.18	394689.51	
B ASSETS			
1 Non-current assets			
(a) Fixed assets	223137.90	228177.37	
(b) Non-current investments	12557.25	14890.29	
(c) Long-term loans and advances	34942.48	25317.19	
(d) Other non-current assets	8180.87	5127.77	
Sub-total- Non-current assets	278818.50	273512.62	
Current assets			
(a) Inventories	55318.48	62359.91	
(b) Trade receivables	11481.35	9130.93	
(c) Cash and cash equivalents	2108.29	16958.51	
(d) Short-term loans and advances	45323.56	32727.54	
Sub-total-current assets	114231.68	121176.89	
TOTAL ASSETS	393050.18	394689.51	
For and on behalf of the Board			
			
S Krishnan			
Executive Director - Finance			
Place : Chennai			
Date : November.09, 2012			

**Media release****Chennai, India – November 09, 2012****Orchid Pharma registers sale of Rs 330 crore in Q2 FY13****Net loss on account of working capital constraints & higher interest outflow****Financial highlights for Q2 FY13 (On Standalone basis)**

- Total income of Rs 330.54 crore (US\$ 62.53 million)
- EBIDTA of Rs 85.67 crore (US\$ 16.20 million)
- PBT stood at a loss of Rs 30.35 crore (US\$ 5.74 million)
- PAT registered a loss of Rs 19.95 crore (US\$ 3.77 million)

Financial highlights for Q2 FY13 (On consolidated basis)

- Total income of Rs 378.37 crore (US\$ 71.57 million)
- EBIDTA of Rs 83.65 crore (US\$ 15.83 million)
- PBT stood at a loss of Rs 33.98 crore (US\$ 6.42 million)
- PAT registered a loss of Rs 24 crore (US\$ 4.54 million)

The above numbers include the exceptional gain/loss on account of the profit on stake sale in the Chinese JV and the exchange loss on Foreign Currency loans aggregating to Rs 46.22 crore.

Financial highlights for H1 FY13 (On Standalone basis)


- Total income of Rs 687.78 crore (US\$ 130.11 million)
- EBIDTA of Rs 133.4 crore (US\$ 25.24 million)
- PBT stood at a loss of Rs 93.85 crore (US\$ 17.75 million)
- PAT stood at a loss of Rs 70.75 crore (US\$ 13.38 million)

Financial highlights for H1 FY13 (On consolidated basis)

- Total income of Rs 785.08 crore (US\$ 148.52 million)
- EBIDTA of Rs 129.68 crore (US\$ 24.53 million)
- PBT stood at a loss of Rs 100.71 crore (US\$ 19.05 million)
- PAT registered a loss of Rs 78.03 crore (US\$ 14.76 million)

'Orchid Towers', #313, Valluvar Kottam High Road, Nungambakkam, Chennai 600 034 INDIA

Q2 / H1 FY13 earnings



09/11/12



The above numbers include the exceptional gain/loss on account of the profit on stake sale in the Chinese JV and the exchange loss on Foreign Currency loans aggregating to Rs 38.14 crore.

Q2 earnings (for the quarter ended September 30, 2012) - Standalone

Orchid achieved a total income of Rs 330.54 crore (US\$ 62.53 million) for the quarter ended September 30, 2012 (Q2 FY13) in comparison to Rs 419.49 crore (US\$ 79.36 million) registered during the corresponding quarter of the last fiscal. Earnings before Interest, Depreciation & Tax (EBIDTA) stood at Rs 85.67 crore (US\$ 16.20 million) compared to Rs 99.47 crore (US\$ 18.82 million) of the corresponding quarter of last year. The Profit before Tax (PBT) stood at a loss of Rs 30.35 crore (US\$ 5.74 million) compared to a profit of Rs 23.43 crore (US\$ 4.43 million) registered during the corresponding Q2 of the last fiscal. The net profit after tax stood at a loss of Rs 19.95 crore (US\$ 3.77 million) compared to a profit of Rs 23.43 crore (US\$ 4.43 million) of the corresponding quarter of the last fiscal. Earnings per share stood at a negative of Rs 2.83 during this period.

Q2 earnings (for the quarter ended September 30, 2012) - Consolidated


Orchid achieved a total income of Rs 378.37 crore (US\$ 71.57 million) for the quarter ended September 30, 2012 (Q2 FY13) in comparison to Rs 465.71 crore (US\$ 88.10 million) registered during the corresponding quarter of the last fiscal. Earnings before Interest, Depreciation & Tax (EBIDTA) stood at Rs 83.65 crore (US\$ 15.83 million) compared to Rs 97.97 crore (US\$ 18.53 million) of the corresponding quarter of last year. The Profit before Tax (PBT) for the second quarter (Q2) stood at a loss of Rs 33.98 crore (US\$ 6.42 million) compared to a profit of Rs 20.94 crore (US\$ 3.96 million) during the corresponding Q2 of the last fiscal. The net profit after tax stood at a loss of Rs 24 crore (US\$ 4.54 million) compared to a profit of Rs 20.72 crore (US\$ 3.92 million) of the corresponding Q2 of the last fiscal. Earnings per share stood at a negative of Rs 3.40 during this period.

H1 earnings (for the half year ended September 30, 2012) - Standalone

Orchid's revenues on a standalone basis, for the half-year (H1) ended September 30, 2012 stood at Rs 687.78 crore (US\$ 130.11 million) compared to Rs 803.08 crore (US\$ 151.92 million) registered during the corresponding period of the previous fiscal.

'Orchid Towers', #313, Valluvar Kottam High Road, Nungambakkam, Chennai 600 034 INDIA

Q2 / H1 FY13 earnings



09/11/12



Earnings before Interest, Depreciation & Tax (EBIDTA) stood at Rs 133.4 crore (US\$ 25.24 million) compared to Rs 185.37 crore (US\$ 35.07 million) registered during the corresponding H1 of the last fiscal. The net profit after tax stood at a loss of Rs 70.75 crore (US\$ 13.38 million) compared to a profit of Rs 38.97 crore (US\$ 7.37 million) of the corresponding H1 of the last fiscal. Earnings per share stood at a negative of Rs 10.04 during this period.

H1 earnings (for the half year ended September 30, 2012) - Consolidated

On a consolidated basis, Orchid's revenues for the half-year (H1) ended September 30, 2012 stood at Rs 785.08 crore (US\$ 148.52 million) compared to Rs 914.94 crore (US\$ 173.08 million) registered during the corresponding period of last fiscal. Earnings before Interest, Depreciation & Tax (EBIDTA) stood at Rs 129.68 crore (US\$ 24.53 million) compared to Rs 186.91 crore (US\$ 35.36 million) registered during the corresponding H1 of the last fiscal. The net profit after tax stood at a loss of Rs 78.03 crore (US\$ 14.76 million) compared to a profit of Rs 37.65 crore (US\$ 7.13 million) of the corresponding H1 of the last fiscal. Earnings per share stood at a negative of Rs 11.07 during this period.

*** 1 US\$ = Rs 52.86**

Comment from the Chairman & Managing Director

"The increased interest outflow and the continuing liquidity pressure leading to working capital constraints have impacted the revenues and profitability during the second quarter / half year. This continuing pressure will lead to the current financial year witnessing a flat trend in terms of our overall performance. We are working on a long-term growth strategy encompassing both the existing business verticals and foray into new product segments which should improve the revenue and margin profile next fiscal onwards", said Mr K Raghavendra Rao, Chairman & Managing Director, Orchid Chemicals & Pharmaceuticals Ltd.


Regulatory update

Filings

API

'Orchid Towers', #313, Valluvar Kottam High Road, Nungambakkam, Chennai 600 034 INDIA

Q2 / H1 FY13 earnings



09/11/12



In the API (Active Pharmaceutical Ingredients) space, Orchid's cumulative filings of its US DMFs stood at 89. The break-up of the total filings is 28 in the Cephalosporin space, 47 in NPNC space, 2 in the Betalactam segment and 12 in the Carbapenems segment.

The cumulative filings of COS (Certificate of Suitability) for the European market stood at 21 which includes 14 in Cephalosporin space, 6 in NPNC space and 1 in the Betalactam segment.

Finished Dosage Forms (FDF)

Orchid's cumulative ANDA filings for the US market stands at 43. This includes 8 Para IV FTF (First-To-File) filings. The break-up of the total ANDA filings is 13 in Cephalosporins space and 30 in NPNC space.

In the EU region the cumulative count of Marketing Authorizations (MAs) filed stood at 30. The break-up of the total MA filings is 15 in Cephalosporin space and 15 in the NPNC space.

Approvals

The approved ANDAs count rose to 31 (including 3 tentative approvals) at the end of Q2 FY13. The break-up of the total ANDA approval count comprises of 11 in Cephalosporin space and 20 in NPNC space.

In the EU region the cumulative count of Marketing Authorizations (MA) approval stands at 22. The break-up of the total MA approval count is 10 in the Cephalosporin space and 12 in the Oral NPNC space.


With staunch efforts on product development, Orchid's filing and approval count is poised to increase in the coming months and quarters.

About Orchid Pharma

Orchid Chemicals & Pharmaceuticals Ltd. is a leading pharmaceutical company headquartered in Chennai, India involved in the development, manufacture and marketing of diverse bulk actives, formulations and Nutraceuticals. With exports spanning more than 75 countries, Orchid is the largest manufacturer-exporter of cephalosporin bulk actives in India and is ranked amongst the Top 5-cephalosporin producers in the world.

'Orchid Towers', #313, Valluvar Kottam High Road, Nungambakkam, Chennai 600 034 INDIA

Q2 / H1 FY13 earnings



09/11/12




Orchid's world-class manufacturing infrastructure including USFDA and UK MHRA approved API and oral dosage form facilities are located at Chennai and Aurangabad. Orchid has dedicated state-of-the-art GLP compliant R&D centres for API research, drug discovery and pharmaceutical research at Chennai. Orchid has ISO 9001:2000, ISO 14001 and OHSAS 18001 certifications. Orchid is listed on the National Stock Exchange (NSE), Bombay Stock Exchange (BSE) and the Madras Stock Exchange (MSE) in India. Orchid is also working on developing new chemical entities in six therapeutic areas.

For additional information, please visit www.orchidpharma.com

Safe Harbour

"This media release includes forward looking statements and indications, which are based on current expectations and forecasts about future events. Such statements and indications involve known and unknown risks, uncertainties and other factors and may cause actual results to materially differ. Such factors include, but are not limited to, changes in local and global economic conditions, Orchid's ability to successfully implement strategies, the market acceptance and demand of Orchid's products and services, Orchid's growth rates, expansion, technological change and Orchid's exposure to market risks. By their nature, these statements and indications are only estimates and actual results could differ from these in the future."

For ORCHID CHEMICALS
& PHARMACEUTICALS LTD.


Sr.GM - Legal & Company Secretary

'Orchid Towers', #313, Valluvar Kottam High Road, Nungambakkam, Chennai 600 034 INDIA

SNB ASSOCIATES

CHARTERED ACCOUNTANTS

12, 3rd Floor, Gemini Parsn Complex, 121 Mount Road, Chennai - 600 006.

AUDITORS' REPORT**TO THE BOARD OF DIRECTORS OF
ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED****ON LIMITED REVIEW OF UNAUDITED FINANCIAL RESULTS
FOR THE PERIOD ENDED SEPTEMBER 30, 2012**

We have reviewed the accompanying statement of unaudited financial results of **ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED** ("the Company") for the period ended 30th September 2012 except for the disclosures regarding "Public Shareholding" and "Promoter and Promoter Group Shareholding", which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

During the Quarter and Half year ended 30th September 2012 the company has accounted profit on sale of Investments amounting Rs.5126.48 Lakhs shown under exceptional items. The company has signed and delivered the share transfer deeds in accordance with agreement entered with the buyer to the escrow holder, which is pending to be delivered to the buyer as at 30.09.2012. The company has obtained a legal opinion that the sale is complete and accordingly has recognized the profit.

Subject to the above, based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is disclosed, or that it contains any material misstatements except for the figures of consolidated results of the company which were not reviewed by us.

Date: 9th November 2012
Place: Chennai



For SNB ASSOCIATES
Chartered Accountants
Firm Registration No. 015682N


B. Mahalingam
Partner
Membership No. 210408

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR / QUARTER ENDED SEPTEMBER 30, 2012

Orchid Chemicals

& Pharmaceuticals Limited

Rs. lakhs

S. No.	Particulars	Standalone					
		Unaudited					Audited
		Three months ended 30-Sep-12	Three months ended 30-Jun-12	Three months ended 30-Sep-11	Six months ended 30-Sep-12	Six months ended 30-Sep-11	Year ended 31-Mar-12
1	Income from Operations						
	a) Net Sales / Income from Operations (Net of Excise Duty)	33054.81	31563.15	41222.25	64617.96	78598.27	170170.80
	b) Other Operating Income	-	4159.90	726.97	4159.90	1709.84	6283.47
	c) Total income from operations (Net) (a+b)	33054.81	35723.05	41949.22	68777.86	80308.11	176464.27
2	Expenses						
	a) Cost of materials consumed	15202.02	10193.28	18363.10	25395.30	40341.82	80241.50
	b) Purchases of stock-in-trade	1420.27	1538.32	1129.29	2958.59	2564.83	4546.38
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(914.03)	7204.14	(641.03)	6290.11	(5487.43)	(6201.86)
	d) Employee benefit expense	4130.37	3761.80	3568.60	7892.17	7435.39	15464.59
	e) Depreciation / Amortisation	3955.09	3991.26	3597.59	7946.35	7128.06	14905.56
	f) Other Expenses	9272.27	7444.46	8938.37	16716.73	16097.67	41242.32
	g) Total Expenses	33065.99	34133.26	34955.92	67199.25	68080.44	150198.49
3	Profit/(Loss) from operations before other income, finance costs, exceptional items (1-2)	(11.18)	1589.79	6993.30	1578.61	12227.67	26265.78
4	Other Income	1.31	-	1.30	1.31	1.30	1.59
5	Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)	(9.87)	1589.79	6994.60	1579.92	12228.97	26267.37
6	Finance costs	7647.05	7132.58	4006.69	14779.64	7081.43	17905.29
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)	(7656.92)	(5542.80)	2987.91	(13199.72)	5147.54	8362.08
8	Exceptional Items - Gain / (Loss)	4621.98	(808.04)	(8644.71)	3813.94	(8819.27)	(8388.14)
9	Profit/(Loss) from ordinary activities before Tax (7+8)	(3034.94)	(6350.84)	(5656.80)	(9385.78)	(3671.73)	(26.06)
10	Tax expenses						
	- Current Tax & Deferred Tax	(1040.33)	(1270.66)	-	(2310.89)	430.82	(2337.22)
11	Net Profit/(Loss) from ordinary activities after Tax (9-10)	(1994.61)	(5080.18)	(5656.80)	(7074.79)	(4102.55)	2311.16
12	Extraordinary item (net of tax expenses Rs.nil)	-	-	8000.00	-	8000.00	8000.00
13	Net Profit/(Loss) for the period (11+12)	(1994.61)	(5080.18)	2343.20	(7074.79)	3897.45	10311.16
14	Paid-up Equity Share Capital (Face value of Rs.10/- each)	7045.21	7045.21	7044.21	7045.21	7044.21	7044.21
15	Reserves excluding Revaluation Reserves	-	-	-	-	-	112410.89
16	Earnings per share (EPS) before extra-ordinary items of Rs.10/- each						
	- Basic Rs.	(2.83)*	(7.21)*	(8.03)*	(10.04)*	(5.82)*	3.28
	- Diluted Rs.	(2.83)*	(7.21)*	(8.03)*	(10.04)*	(5.82)*	3.24
17	Earnings per share (EPS) after extra-ordinary items of Rs.10/- each						
	- Basic Rs.	(2.83)*	(7.21)*	3.33*	(10.04)*	5.53*	14.64
	- Diluted Rs.	(2.83)*	(7.21)*	2.75*	(10.04)*	4.57*	14.46
A	PARTICULARS OF SHAREHOLDING						
1	Public Shareholding						
	- Number of equity shares	47611295	47611295	49427854	47611295	49427854	47601295
	- Percentage of Shareholding	67.58	67.58	70.17	67.58	70.17	67.57
2	Promoters and Promoter group shareholding						
	a. Pledged / Encumbered						
	- Number of shares	17676037	17110383	16210383	17676037	16210383	17060383
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	77.39	74.91	77.14	77.39	77.14	74.69
	- Percentage of shares (as a % of the total share capital of the company)	25.09	24.29	23.01	25.09	23.01	24.22
	b. Non - Encumbered						
	- Number of shares	5164744	5730398	4803839	5164744	4803839	5780398
	- Percentage of shares (as a % of the total shareholding of the promoter and promoter group)	22.61	25.09	22.86	22.61	22.86	25.31
	- Percentage of shares (as a % of the total share capital of the company)	7.33	8.13	6.82	7.33	6.82	8.21
B	INVESTOR COMPLAINTS						
	Pending at the beginning of the quarter						
	Received during the quarter						
	Disposed off during the quarter						
	Remaining unresolved at the end of the quarter						

3 Months ended 30-Sep-2012

- NIL -



32


32

- NIL -


/CERTIFIED TRUE COPY/

For ORCHID CHEMICALS & PHARMACEUTICALS LTD




* EPS for the period (not annualised)																																		
The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 09, 2012 and have been subjected to limited review by the Statutory Auditors in terms of Clause 41 of the Listing Agreement.																																		
The Company is operating in single segment (i.e) "Pharmaceuticals".																																		
<table border="1"> <tr> <th>Consolidated Results of the company</th> <th>Three months ended 30-Sep-12</th> <th>Three months ended 30-Jun-12</th> <th>Three months ended 30-Sep-11</th> <th>Six months ended 30-Sep-12</th> <th>Six months ended 30-Sep-11</th> <th>Year ended 31-Mar-12</th> </tr> <tr> <td>Total Operating Income</td> <td>37837.16</td> <td>40670.74</td> <td>46571.68</td> <td>78507.90</td> <td>91484.89</td> <td>190189.09</td> </tr> <tr> <td>EBIDTA</td> <td>8365.54</td> <td>4602.86</td> <td>9797.09</td> <td>12968.40</td> <td>18691.32</td> <td>40892.58</td> </tr> <tr> <td>Profit After Tax</td> <td>(2400.25)</td> <td>(5402.51)</td> <td>2072.81</td> <td>(7802.77)</td> <td>3765.06</td> <td>9747.84</td> </tr> </table>							Consolidated Results of the company	Three months ended 30-Sep-12	Three months ended 30-Jun-12	Three months ended 30-Sep-11	Six months ended 30-Sep-12	Six months ended 30-Sep-11	Year ended 31-Mar-12	Total Operating Income	37837.16	40670.74	46571.68	78507.90	91484.89	190189.09	EBIDTA	8365.54	4602.86	9797.09	12968.40	18691.32	40892.58	Profit After Tax	(2400.25)	(5402.51)	2072.81	(7802.77)	3765.06	9747.84
Consolidated Results of the company	Three months ended 30-Sep-12	Three months ended 30-Jun-12	Three months ended 30-Sep-11	Six months ended 30-Sep-12	Six months ended 30-Sep-11	Year ended 31-Mar-12																												
Total Operating Income	37837.16	40670.74	46571.68	78507.90	91484.89	190189.09																												
EBIDTA	8365.54	4602.86	9797.09	12968.40	18691.32	40892.58																												
Profit After Tax	(2400.25)	(5402.51)	2072.81	(7802.77)	3765.06	9747.84																												
The Company has entered into a Business Transfer Agreement (BTA) dated August 29, 2012 with Hospira Healthcare India Private Limited for the sale and transfer of Orchid's Penicillin and Penem API business and the API facility located in Aurangabad (Maharashtra) together with an associated Process R&D infrastructure located in Chennai.																																		
The Board has approved the transfer of Orchid's 50% equity holding of its Joint venture NCPC, Orchid Pharmaceuticals Co.Ltd, China to Joint Venture partner in China.																																		
Exceptional items for the quarter ended September 30, 2012 represents profit on sale of investments in the Joint Venture in China of Rs. 5126.48 lakhs (Previous period - Rs. NIL), exchange loss on FCCBs / FCTLs of Rs.504.5 lakhs (Corresponding quarter - Loss of Rs. 7582.30 lakhs) and one time closure cost of Alathur Plant for the quarter ended September 2012 is Rs. NIL (Previous period - Rs.1129.71 lakhs). The Company had exercised the option provided under the Amendment to the Companies (Accounting Standards) Amendments Rules, 2006 dated March 31, 2009. The Ministry of Corporate Affairs vide notification dated 29th December 2011 has extended the amortisation of gains or losses arising on reporting of Foreign Currency Monetary Items over the balance period of such long term asset / liability. Accordingly Exchange Loss on long term foreign currency loans have been amortised over the balance period of such loans. The amount remaining to be amortized in the financial statements as at September 30, 2012 on account of exercising the above option is Rs.7883.02 lakhs (Corresponding period ended - Rs.NIL).																																		
Previous period figures have been regrouped wherever necessary.																																		
<p style="text-align: right;">For and on behalf of the Board</p> <p style="text-align: right;"></p> <p style="text-align: right;">S Krishnan Executive Director - Finance</p> <p>Place : Chennai Date : November 09, 2012</p>																																		

/ CERTIFIED TRUE COPY /


For ORCHID CHEMICALS
& PHARMACEUTICALS LTD.
Sr. GM - Legal & Company Secretary



STATEMENT OF ASSETS AND LIABILITIES			
		Rs. lakhs	
Particulars	Standalone		
	Audited		
	As at 30-Sep-12	As at 31-Mar-12	
A EQUITY AND LIABILITIES			
1 Shareholders' funds			
(a) Share Capital	7045.21	7044.21	
(b) Reserves and Surplus	105351.70	112410.88	
Sub-total- Shareholders' funds	112396.91	119455.09	
2 Non-current liabilities			
(a) Long-term borrowings	83529.76	107414.70	
(b) Deferred tax liabilities (net)	14807.35	17118.34	
(c) Other long-term liabilities	5447.61	4634.08	
(d) Long-term provisions	771.97	771.97	
Sub-total- Non-current liabilities	104556.69	129939.09	
3 Current liabilities			
(a) Short-term borrowings	78578.07	63788.32	
(b) Trade payables	27178.81	35763.29	
(c) Other current liabilities	66340.78	40654.62	
(d) Short-term provisions	3998.92	5089.10	
Sub-total-Current liabilities	176096.58	145295.33	
TOTAL-EQUITY AND LIABILITIES		393050.18	394689.51
B ASSETS			
1 Non-current assets			
(a) Fixed assets	223137.90	228177.37	
(b) Non-current investments	12557.25	14890.29	
(c) Long-term loans and advances	34942.48	25317.19	
(d) Other non-current assets	8180.87	5127.77	
Sub-total- Non-current assets	278818.50	273512.62	
Current assets			
(a) Inventories	55318.48	62359.91	
(b) Trade receivables	11481.35	9130.93	
(c) Cash and cash equivalents	2108.29	16958.51	
(d) Short-term loans and advances	45323.56	32727.54	
Sub-total-current assets	114231.68	121176.89	
TOTAL ASSETS		393050.18	394689.51
For and on behalf of the Board			
			
Place : Chennai		S Krishnan	
Date : November.09, 2012		Executive Director - Finance	



7 CERTIFIED TRUE COPY
For ORCHID CHEMICALS
& PHARMACEUTICALS LTD.


 Sr. GM - Legal & Company Secretary